Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,267.84 -39.17 (-0.74%) Dow
39,065.26 -605.78 (-1.53%) Nasdaq
16,736.03 -65.51 (-0.39%) Bitcoin USD
67,873.20 -1,555.80 (-2.24%) CMC Crypto 200
1,458.14 -44.52 (-2.96%)
Ocular Therapeutix, Inc. (0OT.F)
| Previous close | 5.62 |
| Open | 5.48 |
| Bid | 5.28 x 140000 |
| Ask | 5.38 x 140000 |
| Day's range | 5.37 - 5.48 |
| 52-week range | 1.88 - 10.81 |
| Volume | |
| Avg. volume | 360 |
| Market cap | 831.444M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
Financial Performance and Strategic Developments Highlighted
- Benzinga
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
On Thursday, Ocular Therapeutix Inc (NASDAQ:OCUL) announced topline results from the Phase 1 HELIOS study evaluating Axpaxli versus sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy without diabetic macular edema (DME). 6 of 13 (46.2%) patients in the Axpaxli group experienced a 1 or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks, with 2 of the 6 having a 2-step improvement. No patients in the control group showed 1
- Zacks
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
